Invention Grant
- Patent Title: 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-i-yl) ureas as P38 mapkinase inhibitors
-
Application No.: US16285762Application Date: 2019-02-26
-
Publication No.: US10738032B2Publication Date: 2020-08-11
- Inventor: Kazuhiro Ito , Catherine Elisabeth Charron , John King-Underwood , Stuart Thomas Onions , Alistair Ian Longshaw , Rudy Broeckx , Walter Filliers , Alex Copmans
- Applicant: RESPIVERT LIMITED
- Applicant Address: GB Buckinghamshire
- Assignee: Respivert Limited
- Current Assignee: Respivert Limited
- Current Assignee Address: GB Buckinghamshire
- Agency: Hogan Lovells US LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@54f88a7f com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@43706f66 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@a578484 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@2e6dfd6a
- Main IPC: C07D403/12
- IPC: C07D403/12 ; A61K31/4155 ; C07D491/10 ; A61K31/215 ; A61K31/351 ; A61K31/513 ; A61K31/506
Abstract:
There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
Public/Granted literature
Information query
